よくある質問

What is Tildrakizumab used for?

This biologic medication is an injection used to treat moderate to severe plaque psoriasis in adults whose disease has not responded adequately to other treatments. It works by blocking interleukin-23, an immune protein that drives the inflammation responsible for psoriasis plaques. It is typically given as two starter injections four weeks apart, then once every twelve weeks.

Is Tildrakizumab an approved drug?

Yes, Tildrakizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

• ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108681. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.